Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim AnalysisRead the press release

Results of the Combined General Meeting on May 10, 2021Read the press release

Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholdersRead the press release

Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMDRead the press release

Biophytis – Convening of Another Combined General Meeting at a Later DateRead the press release 

Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021Read the presse release

Biophytis Identifies False Report Regarding COVA StudyRead the Press Release

Biophytis gives updates on its Phase 2-3 COVA study on COVID-19

Read the Press Release

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd

Read the press release

Biophytis AGM meeting will take place on April 26, 2021. Read the Press Release

Biophytis Reports 2020 Full Year Results. Read the Press Release

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium. Read the Press Release

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market. Read the Press Release

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext.Read the Press Release 

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth. Read the Press Release

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market. Read the Press Release

Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing. Read the Press Release

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”). Read the Press Release

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19. Read the Press Release

Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021. Read the Press Release

Bast patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release

Biophytis Presents SARA-OBS study results at the Annual Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Read the Press Release

First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

Upcoming Potential Value Generating Milestones. Read the Press Release

Biophytis is participating to:
– The Geneva European Midcap digital event, December 1rst & 2 2020
– The “Anticovid” Biotech sector conference organized by the SFAF on Wednesday, December 9
– The 13^th International SCWD virtual conference, December 11-13 2020

Paris Court of Appeal rules in Biophytis’ favor in connection with the dispute with NEGMA. Read the Press Release

Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophitys will participate in the following events:

• Mid-Cap Event :October 19 & 20^th
• Galien Week of Innovation: Oct 26-30

First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST. Read the Press Release

Biophytis announces a € 10 million capital increase through private placement. Read the Press Release

Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release

Biophytis Reports H1 2020 Financial Results and Provides Business Update. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release

Biophytis recently attended the Digital ChinaBio conference taking place August 25-27, and will also attend the following conferences:

• The HC Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020 (Virtual Conference)
• The HTID (Health Tech Innovation Days): October 5^th & 6^th, Paris
• Bio Europe Fall : October 26-29^th (Virtual Conference)

Biophytis Enrolls First Patient in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia. Read the Press Release

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure.  Read the Press Release

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces a € 6.1 million capital increase through private placement. Read the Press Release

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANE. Read the Press Release

Biophytis successfully completes a € 4 million capital increase to strengthen its financial structure. Read the Press Release

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

Biophytis announces the issue of 2,050,000 new shares in a capital increase reserved for NEGMA. Read the Press Release

Results of the Combined General Meeting of May 28, 2020: All ordinary and extraordinary resolutions have been adopted. Read the Press Release

Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders. Read the Press Release

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release

Biophytis shares resume trading following the implementation of measures ordered in connection with a dispute with NEGMA. Read the Press Release

Convening of another combined General Meeting at a Later Date. Read the Press Release

Biophytis shares and BSA trading is suspended pending a new press release. Read the Press Release

Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders. Read the Press Release

Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA). Read the Press Release

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders.  Read the Press Release

Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19. Read the Press Release

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release

Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release

2019 Annual Financial Report made available. Read the Press Release

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release

Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release

Biophytis shares trading is suspended pending a new press release. Read the Press Release

Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release

Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release

Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release

Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA. Read the Press Release

Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany. Read the Press Release

Biophytis to attend 11th Geneva MidCap Event. Read the Press Release

Biophytis to participate in the 6th China Healthcare Summit organized by BioCentury and BayHelix in Shanghai. Read the Press Release

Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD. Read the Press Release

Biophytis to attend BIO-Europe® in Hamburg. Read the Press Release

Biophytis Files Protocol Amendment to Optimize the SARA-INT Phase 2b Clinical Trial for Sarcopenia.  Read the Press Release

Biophytis Reports H1 2019 Financial Results and Provides Business Update. Read the Press Release

Biophytis to attend The Galien MedStartUp 2019 Event in New York. Read the Press Release

Biophytis to attend the European Large & MidCap Event in Paris. Read the Press Release

Biophytis to Present Four Posters at the 24th Annual Congress of the World Muscle Society (WMS) in Copenhagen, Denmark. Read the Press Release

Biophytis to Present at the 15th International Congress of the European Geriatric Medicine Society in Krakow, Poland. Read the Press Release

Biophytis to Present at 15th International Pharma Licensing Symposium in Paris. Read the Press Release

Biophytis has signed €24m bond funding from Negma to continue the development of its drug candidates to treat neuromuscular diseases. Read the Press Release

Shareholders Aprove All Resolutions of the Extraordinary General Meeting held on August 8, 2019. Read the Press Release

Biophytis Withdraws Registration Statement for Global Offering. Read the Press Release

Biophytis Announces Filing of Amendment to Registration Statement for Global Offering. Read the Press Release

Biophytis Announces the Launch of its Public Offering on Nasdaq. Read the Press Release

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders. Read the Press Release

Biophytis Announces it Presented One Oral and One Poster Presentation at the MaculART meeting in Paris, France. Read the press release

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon). Read the Press Release

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer. Read the Press Release

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States. Read the Press Release

Biophytis announces suspension of trading until distribution of a press release. Read the Press Release

Biophytis announces that trading of the stock will resume on May 23rd, 2019, at market opening. Read the Press Release

Biophytis announces publication of its 2018 Annual Report. Read the Press Release

Biophytis Presented A Poster at The Association for Research in Vision and Ophthalmology Annual Meeting. Read the Press Release

Biophytis announces the release of the 2018 Annual Financial Report and the departure of Jean-Gérard Galvez from the Board of Directors. Read the Press Release

Biophytis to participate in several investors’ events during the month of April. Read the Press Release

Biophytis Announces One Oral and Four Poster Presentations at the Myology 2019 Congress. Read the Press Release

Biophytis Announces Upcoming Poster Presentations at Scientific Conferences. Read the Press Release

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update. Read the Press Release

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Research. Read the Press Release

Biophytis will attend the annual JP Morgan Healthcare conference, of January 7th to 10th in San Francisco

Biophytis strengthens its senior management team and continues its expansion in the United States. Read the Press Release

Biophytis Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting. Read the Press Release

Biophytis to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular Diseases. Read the Press Release

Interim results 2018 and perspective on activity. Read the Press Release

Biophytis obtains a €10 million loan with Kreos Capital. Read the Press Release

Biophytis Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia. Read the Press Release

BIOPHYTIS to Present at the H.C. Wainwright 20th Annual Global Investment Conference. Read the Press Release

BIOPHYTIS: 2017 Annual Report filed. Read the Press Release

Biophytis appoints a new Chief Medical Officer based in the USA. Read the Press Release

Results of the Extraordinary General Meeting held on June 4, 2018. Passing of all the resolutions. Read the Press Release

Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release

Inclusion of the first patient in Phase 2b Study in Sarcopenia. Read the Press Release

Results of the 2018 Annual Meeting of Shareholders. Read the Press Release

Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release

2017 Annual Financial Report made available. Read the Press Release

BIOPHYTIS updates on clinical development of Macuneos and presents its effects on visual function in a preclinical model of AMD at 2018 ARVO Congress. Read the Press Release

BIOPHYTIS : 2017 Full Year Results. Read the Press Release

Biophytis files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release

Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami. Read the Press Release

Biophytis to participate in upcoming sectorial events over the first half of 2018. Read the Press Release

Biophytis to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018. Read the Press Release

Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD). Read the Press Release

Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium. Read the Press Release

Biophytis completes a € 7,5 M capital increase to help accelerate pipeline programs in orphan pediatric diseases. Read the press release

Biophytis has FDA Approval to initiate SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia. Read the Press Release

Biophytis appoints Professor Thomas Voit to Scientific Advisory Board to help accelerate pipeline programs in orphan pediatric diseases. Read the Press Release

Half-Year Financial Report as of June 30, 2017. Read the press release

Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release

Interview of Stanislas Veillet, CEO of Biophytis for the European Large & Midcap event 2017 with Didier Testot, journalist on the Web tv www.labourseetlavie.com

Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia. Read the Press Release

Biophytis to participate in upcoming industry and investors conferences. Read the Press Release

Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release

Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy . Read the Press Release

The report of the Key Opinion Leader Breakfast of july 28, in NYC with Roger Fielding, PhD (Tufts University) made available

Biophytis announces the appointment of Dr Manfred Horst as Business Development Office. Read the Press Release

2016 Reference Document made available. Read the Press Release

BIOPHYTIS selects Appletree CI Group to conduct MACA-OBS, and releases the MACA clinical program schedule of Macuneos in dry AMD. Read the Press Release

Biophytis to Host Key Opinion Leader Breakfast on Sarcopenia in New York – July 28, 8:00 am

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

Participation of Biophytis to the European MIDCAP event in Hotel Pullman Paris Eiffel Tour – June 28 & 29, 2017

Results of the General Shareholders’ Meeting held on June 16, 2017. Read the Press release

BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study of Macuneos in dry AMD. Read the Press Release

Participation of Biophytis to Bio€quity Europe 2017. May 22-23, 2017. Marriott Rive Gauche, Paris, France

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia. Read the Press Release

BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial. Read the Press Release

Results 2016 Read the Press Release

Biophytis secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT. Read the Press Release

Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study. Read the Press Release

Biophytis to present four scientific studies at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona. Read the Press Release

Full results of SARA-PK study confirm Sarconeos’ good pharmacokinetic profile in elderly patients. Read the Press Release

Biophytis relocates to Pierre and Marie Curie University (UPMC) campus and solidifies creation of leading translational platform for age-related disease. Read the Press Release

BIOPHYTIS to participate to the JP Morgan Annual Healthcare Conference in San Francisco, January 9-12th 2017. Read the Press Release.

Biophytis presents preliminary clinical data of SARA-PK, and new preclinical data of Sarconeos for treating sarcopenia. Read the Press Release

BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile. Read the Press Release

Conférence Biotech Agora – December 13, 2016
18h45 – Hôtel ATALA, 10 Rue de Chateaubriand, 75008

BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients. Read the Press Release

Biophytis Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting. Read the Press Release

BIOPHYTIS to attend to Jefferies conference (London) and European Midcap event (Geneva). Read the Press Release

BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B. Read the Press Release

BIOPHYTIS to implement company’s SARA-data e-Health platform for clinical development of Sarconeos in sarcopenia patients. Read the Press Release

Biophytis to attend the European Large & Midcap Event in Paris – 5-6 October, 2016

Business Update and Consolidated Half-Year Financials as of June 30, 2016. Read the Press Release

BIOPHYTIS launches the second phase of Sarconeos pharmacokinetics study (SARA-PK) after successful completion of the initial phase. Read the Press Release

BIOPHYTIS ready to launch SARA-OBS trial. Read the Press Release

Biophytis will be present at BIOPHARM AMERICA 2016 in Boston, from September 13 to 15

BIOPHYTIS will present at the Rodman & Renshaw 18th Annual Global Investment Conference In New York City, September 11-13, 2016. Read the Press Release

Enrollment of the first subjects in the pharmacokinetics study on Sarcopenia. Read the Press Release

BIOPHYTIS receives approval of bpifrance for an innovation loan of €1.1M to finance the SARA-PK trial. Read the press release

BIOPHYTIS receives Belgian regulatory authorization to start Sarconeos pharmacokinetics study in elderly healthy volunteers (SARA-PK). Read the Press Release

Results of the Combined General Shareholders’ Meeting held on June 10, 2016. Read the Press Release

In french: Assemblée Générale convoquée le 10 juin 2016. Téléchargez le communiqué de presse

BIOPHYTIS unveils its clinical development strategy in the United States, as it communicates its 2015 Document de Référence. Download the Press Release

BIOPHYTIS to Present Key Research Findings on Company’s Two Lead Compounds at Upcoming Scientific Conferences. Read the Press Release

BIOPHYTIS: 2015 Annual Results. Read the Press Release

BIOPHYTIS receives positive scientific advice on SARCOB BIO101 clinical development plan from Belgian regulatory authority. Download the Press Release

L’américain LifeSci Capital initie la couverture du titre Biophytis. Téléchargez le communiqué de presse

Biophytis to present at the Biotech Showcase conference run parallel to the JP Morgan Healthcare Conference (San Francisco, January 11-13, 2016). Read the Press Release

Biophytis Appoints of Roger A. Fielding, Ph.D., as a Scientific Consultant for Company’s SARCOB Clinical Development Program. Download the Press Release

Half-year results for 2015. Download the Press Release

Biophytis Appoints Pierre J. Dilda as Director of Research. Read the Press Release

Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th. Download the Press Release

Biophytis establishes Boston subsidiary to accelerate clinical development. Download the Press Release

BIOPHYTIS Invited to Attend the Jefferies 2015 Global Healthcare Conference. Read the press release

BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity. Click here to download the Press Release

BIOPHYTIS completes an international private placement of 6M€ to conduct its development strategy. Click here to download the Press Release

BIOPHYTIS strengthens its senior management team. Click here to download the Press Release

Biophytis on Alternext Paris

Major mobilisation at the SFO 2015 conference – the 121^st Conference of the Société Française d’Ophtalmologie [French Society of Ophthalmology], from 9 to 12 May 2015, at the Palais des Congrès in Paris

Involvement in the 3^ème Congrès francophone [3^rd French-speaking conference] on assessing fragility in elderly subjects – “Prévention de la Dépendance – Rencontres Scientifiques sur la Sarcopénie” [The Prevention of Dependency – Scientific Fora on Sarcopenia] – Paris, 12 and 13 March 2015.